Cover Image

Advances in Clinical Chemistry: (Volume 41, Advances in Clinical Chemistry).

Bibliographic Details
Main Author: Makowski
Corporate Author: ScienceDirect (Online service)
Format: eBook
Language:English
Published: London, UK ; San Diego, CA : Elsevier Science & Technology, 2006.
Series:Advances in Clinical Chemistry
Subjects:
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Cover
  • Cover Page
  • Contents
  • Contributors
  • Preface
  • Chapter 1: Is Taurine A Biomarker?
  • 1. Taurine
  • 1.1. Nutrition
  • 1.2. Reproduction
  • 1.3. Cardiovascular System
  • 1.4. CNS
  • 1.5. Taurine as an Osmolyte
  • 1.6. Pancreas
  • 1.7. Taurine as an Immunomodulator
  • 1.8. Taurine as a Biomolecule
  • 2. Taurine as a Biomarker
  • 2.1. Blood and Urine Taurine Levels
  • 2.2. Milk Taurine Levels
  • 2.3. Tissue Taurine Levels
  • 2.4. Aging and Taurine
  • 2.5. Myocardial Ischemia and Taurine
  • 3. Conclusions
  • References
  • Chapter 2: Application of Nanoscale Bioassemblies to Clinical Laboratory Diagnostics
  • 1. Introduction
  • 1.1. Nanoscale Bioassemblies
  • 1.2. Scaffolds
  • 2. Protein Scaffolds
  • 2.1. Closed Protein Shells
  • 2.2. Linked Protein Domains
  • 3. DNA Scaffolds
  • 3.1. Single-Stranded Tethers
  • 3.2. Open and Closed Edged Assemblies
  • 3.3. Ordered Display
  • 3.4. Networked Display
  • 4. Organic Polymer Scaffolds
  • 4.1. Cross-Linked Display
  • 4.2. Dendrimer Display
  • 5. Inorganic Scaffolds
  • 5.1. Quantum Dots
  • 5.2. Photonic Crystals
  • 6. Discussion
  • 7. Conclusions
  • References
  • Chapter 3: Cardiac Troponins: Clinical and Analytical Aspects
  • 1. Abstract
  • 2. Introduction
  • 3. Structure and Biochemistry of Troponins
  • 3.1. Troponin C
  • 3.2. Troponin I
  • 3.3. Troponin T
  • 3.4. Implications from the Newly Elucidated Structure of the Core Domain
  • 3.5. Coordinated Regulation of Muscle Contraction
  • 3.6. Kinetics of Release, Degradation, and Clearance of Troponins
  • 3.7. Cardiac Troponin Subunit Release into Serum After Acute Myocardial Infarction
  • 3.8. From Structure to Analysis: Implications for Troponin Assay Development
  • 4. Clinical Significance of Measured Cardiac Troponins
  • 4.1. Role in Diagnosis
  • 4.2. Role in Prognosis and Risk Stratification
  • 4.3. Role in Guidance of Therapy and Interventions
  • 4.4. Role in Other Conditions
  • 5. Measurement of Cardiac Troponins
  • 5.1. The Ideal Cardiac Biomarker
  • 5.2. Cardiac Troponin T
  • 5.3. Cardiac Troponin I
  • 5.4. Point-of-Care Testing/Near-Patient Testing
  • 5.5. Quality Assurance
  • 5.6. How to Use the Currently Available Cardiac Troponin Assays
  • 6. Factors Affecting the Measurement of Cardiac Troponins
  • 6.1. Renal Failure
  • 6.2. Sepsis
  • 6.3. Heterophilic Antibodies
  • 6.4. Rheumatoid Factor
  • 6.5. Autoantibodies
  • 6.6. Antiphospholipid Antibodies
  • 6.7. Proteolysis
  • 6.8. Hemolysis
  • 6.9. Heparin
  • 6.10. Other Conditions and Interferences
  • 7. Conclusions and Future Directions
  • References.